G. Pecher, S. Gillessen, M. Groettup, Thomas Cerny, P. Reichardt, D. Pink, J. Tilgner, A. Kretzschmar, P. Thuss-Patience, B. Dörken, I. Yusim, W. Mermershtain, E. Neulander, I. Eidelberg, I. Gusakova, Jacob Kaneti, R. Steinmeier, S. Sobottka, G. Reiss, J. Bredow, Johannes Gerber, Gabriele Schackert, Markus Joerger, C. Oehlschlegel, M. Neises, G. Kornek, T. Fliedner, W. Queisser, K. Mross, B. Häring, N. Holländer, Stephan Mielke, Dirk Behringer, U. Massing, C. Unger, Ralf A. Hilger, Max E. Scheulen, D. Strumberg, J. Drevs, C. Laus, Michael Medinger, C. Schmidt-Gersbach, M. Uppenkamp, A. C. Feller, C. Landmann
2002.8.1Oncology Research and Treatment
tlooto Summary
Unconjugated sibrotuzumab (BIBH 1), which is a humanised version of the murine anti-FAP mAb F19, was investigated for its anti-tumour activity, safety and pharmacokinetics and was well tolerated and safe.
Abstract
Abstract is not available.
Citation format
PECHER, G., et al. Contents of next issues · themenvorschau. Oncology Research and Treatment, 2002, 25: 608–608.